Huakang Biomedical Holdings Company Limited (HKG:8622)

HKG:8622 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	25.36	24.63	25.33	26.13	21.97
Revenue Growth (YoY)	2.96%	-2.77%	-3.05%	18.94%	-13.76%
Cost of Revenue	8.29	8.54	8.42	9.67	7.25
Gross Profit	17.07	16.09	16.91	16.46	14.72
Selling, General & Admin	19.29	18.49	18.75	17.7	17.32
Research & Development	2.83	2.55	2.48	2.44	2.25
Operating Expenses	22.08	22.81	21.61	20.77	23.02
Operating Income	-5.01	-6.71	-4.7	-4.32	-8.3
Interest Expense	-0.09	-0.05	-0.06	-0.1	-0.07
Interest & Investment Income	0.51	0.4	0.41	0.18	0.19
Earnings From Equity Investments	-	-	-	-	-0.04
Currency Exchange Gain (Loss)	0.24	0.25	0.86	-0.26	-1.07
Other Non Operating Income (Expenses)	0.19	0.33	0.48	0.6	0.47
EBT Excluding Unusual Items	-4.16	-5.78	-3.01	-3.9	-8.83
Asset Writedown	-	-	-	-	-2.56
Other Unusual Items	-	-	-	-	0.01
Pretax Income	-4.16	-5.78	-3.01	-3.9	-11.37
Income Tax Expense	-	-	0.07	0.32	0.26
Net Income	-4.16	-5.78	-3.08	-4.22	-11.63
Net Income to Common	-4.16	-5.78	-3.08	-4.22	-11.63
Shares Outstanding (Basic)	482	416	405	400	400
Shares Outstanding (Diluted)	482	416	405	400	400
Shares Change (YoY)	15.98%	2.80%	1.16%	-	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.03
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.03
Free Cash Flow	-5.05	-1.55	0.64	-4.33	-5.67
Free Cash Flow Per Share	-0.01	-0.00	0.00	-0.01	-0.01
Gross Margin	67.32%	65.34%	66.77%	62.98%	67.00%
Operating Margin	-19.76%	-27.26%	-18.54%	-16.52%	-37.77%
Profit Margin	-16.40%	-23.48%	-12.14%	-16.15%	-52.93%
Free Cash Flow Margin	-19.93%	-6.29%	2.51%	-16.57%	-25.79%
EBITDA	-3.49	-5.11	-2.92	-2.82	-6.45
EBITDA Margin	-13.75%	-20.76%	-11.52%	-10.80%	-29.36%
D&A For EBITDA	1.52	1.6	1.78	1.5	1.85
EBIT	-5.01	-6.71	-4.7	-4.32	-8.3
EBIT Margin	-19.76%	-27.26%	-18.54%	-16.52%	-37.77%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.